Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphangioleiomyomatosis × Everolimus × Clear all

Phase

Phase 4 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10 Carcinoma, Renal Cell 6 Hodgkin Disease 5 Glioblastoma 5 Colorectal Neoplasms 5 Central Nervous System Neoplasms 5 Waldenstrom Macroglobulinemia 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, Mantle-Cell 4 Head and Neck Neoplasms 4 Gliosarcoma 4 Tuberous Sclerosis 3 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Sezary Syndrome 3 Recurrence 3 Prostatic Neoplasms 3 Neoplasms 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Kidney Neoplasms 3

Interventions

carbon-11 acetate 1 Sirolimus 1 Simvastatin 1 Imatinib Mesylate 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02061397 2020-08-25

SOS

University of Pennsylvania

Phase 1/2 Completed

10 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡